Log in

NASDAQ:ANAC - Anacor Pharmaceuticals Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$99.20
+99.20 (+∞)
(As of 06/27/2016)
Add
Today's Range
$99.20
Now: $99.20
$99.20
50-Day Range N/A
52-Week Range
$52.00
Now: $99.20
$156.93
VolumeN/A
Average Volume1.81 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Anacor Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. Its lead product development candidate is crisaborole topical ointment, approximately 2%, a non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the treatment of mild-to-moderate atopic dermatitis and psoriasis. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:ANAC
CUSIP03242010
Phone+1-650-5437500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive ANAC News and Ratings via Email

Sign-up to receive the latest news and ratings for ANAC and its competitors with MarketBeat's FREE daily newsletter.


Anacor Pharmaceuticals (NASDAQ:ANAC) Frequently Asked Questions

What is Anacor Pharmaceuticals' stock symbol?

Anacor Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANAC."

How were Anacor Pharmaceuticals' earnings last quarter?

Anacor Pharmaceuticals Inc (NASDAQ:ANAC) posted its quarterly earnings data on Tuesday, May, 10th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing the Zacks' consensus estimate of ($0.35) by $0.01. The biopharmaceutical company had revenue of $17.54 million for the quarter, compared to the consensus estimate of $19.53 million. Anacor Pharmaceuticals's revenue was up 14.9% on a year-over-year basis. During the same period last year, the company posted ($0.30) EPS. View Anacor Pharmaceuticals' Earnings History.

Has Anacor Pharmaceuticals been receiving favorable news coverage?

Media coverage about ANAC stock has trended very negative this week, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Anacor Pharmaceuticals earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Anacor Pharmaceuticals.

Who are some of Anacor Pharmaceuticals' key competitors?

What other stocks do shareholders of Anacor Pharmaceuticals own?

What is Anacor Pharmaceuticals' stock price today?

One share of ANAC stock can currently be purchased for approximately $99.20.

What is Anacor Pharmaceuticals' official website?

The official website for Anacor Pharmaceuticals is http://www.anacor.com/.

How can I contact Anacor Pharmaceuticals?

Anacor Pharmaceuticals' mailing address is 1020 E Meadow Cir, PALO ALTO, CA 94303-4230, United States. The biopharmaceutical company can be reached via phone at +1-650-5437500.


MarketBeat Community Rating for Anacor Pharmaceuticals (NASDAQ ANAC)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  285 (Vote Outperform)
Underperform Votes:  166 (Vote Underperform)
Total Votes:  451
MarketBeat's community ratings are surveys of what our community members think about Anacor Pharmaceuticals and other stocks. Vote "Outperform" if you believe ANAC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANAC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/8/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel